Role of BRAF V600E Mutation in Papillary Thyroid Cancer
Main Article Content
Abstract
Talking about thyroid carcinomas leaves a fairly wide slope, in which it should be considered not only the variants and their clinical frequency, but the mutant genetic finding that gives preamble to the malignancy, its clinical variability, histological as well as the prognosis. It is important to note that the most frequent thyroid carcinoma in the population is papillary, with an index greater than 80% of all cases, being rare in pediatrics. The papillary thyroid subtype is the result of one of two possible alterations affecting the genes encoding tyrosine kinase, either in the RET gene of chromosome 10q11 or in the BRAF gene, by an early mutation in the MAP kinase signaling pathway. Statistically, it is known that the mutation in the BRAF gene represents most of the alterations that give rise to papillary thyroid carcinoma, and in turn, this BRAF gene presents an alteration in the amino acid 600, which gives rise to the BRAF 600E gene. That is why, in this research work focuses on the role BRAF V600E and papillary thyroid carcinoma, from the pathogenic mechanism that gives rise to the mutation, the genetic location of the mutation. Clinical and histopathological relationship with the BRAF mutation as well as prognosis and certain related complications are mentioned.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145183/pdf/zlj2718.pdf
II. N. Paul Ohori, MD1; Rashi Singhal, MD, MPH1; Marina N. Nikiforova, MD1; Linwah Yip, MD2;Karen E. Schoedel, MD1; Christopher Coyne, MD3; Kelly L. McCoy, MD2; Shane O. LeBeau, MD3;Steven P. Hodak, MD3; Sally E. Carty, MD2; and Yuri E. Nikiforov, MD, PhD. (Julio, 2015). BRAFMutation Detection in Indeterminate ThyroidCytology Specimens. sep, 2018, de Cancer Cytopathology Sitio web: https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.21229
III. https://sci-hub.tw/10.1001/jamaoncol.2016.3288
IV. Dario de Biase, Valentina Cesari, Michela Visani, Gian Piero Casadei, Nadia Cremonini, Greta Gandolfi, Valentina Sancisi, Moira Ragazzi, Annalisa Pession, Alessia Ciarrocchi, and Giovanni Tallini. (April 29, 2014). High-Sensitivity BRAF Mutation Analysis: BRAF V600E Is Acquired Early During Tumor Development but Is Heterogeneously Distributed in a Subset of Papillary Thyroid Carcinomas. Advances in Genetics Endocrine Research, 9.
V. Mingzhao Xing, MD, PhD; Ali S. Alzahrani, MD; Kathryn A. Carson. (April 10, 2013). Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. JAMA Network, 309, 9.
VI. https://www.nejm.org/doi/pdf/10.1056/NEJMoa1209288
VII. http://www.pnas.org/content/pnas/111/16/E1600.full.pdf
VIII. David M. Hyman, M.D., Igor Puzanov, M.D., Vivek Subbiah, M.D., Jason E. Faris, M.D., Ian Chau, M.D., Jean-Yves Blay, M.D., Ph.D., Jürgen Wolf, M.D., Ph.D., Noopur S. Raje, M.D., Eli L. Diamond, M.D., Antoine Hollebecque, M.D., Radj Gervais, M.D., Maria Elena Elez-Fernandez, M.D., Antoine Italiano, M.D., Ph.D., Ralf-Dieter Hofheinz, M.D., Manuel Hidalgo, M.D., Ph.D., Emily Chan, M.D., Ph.D., Martin Schuler, M.D., Susan Frances Lasserre, M.Sc., Martina Makrutzki, M.D., Florin Sirzen, M.D., Ph.D., Maria Luisa Veronese, M.D., Josep Tabernero, M.D., Ph.D., and José Baselga, M.D., Ph.D.. (2015). Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. sep, 2018, de The new england journal o f medicine Sitio web:
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1502309
IX. Iñigo Landa, Ian Ganly, Timothy A. Chan, Norisato Mitsutake, Michiko Matsuse, Tihana Ibrahimpasic, Ronald A. Ghossein, and James A. Fagin. (2013). Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease. Agosto 2018, de Human Oncology and Pathogenesis Program (I.L., T.A.C., J.A.F.) and Departments of Medicine (J.A.F.), Surgery (I.G., T.I.), Radiation Oncology (T.A.C.), and Pathology (R.A.G.), Memorial Sloan-Kettering Cancer Center, New York, New York 10065; and Nagasaki University Research Center for Genomic Instability and Carcinogenesis (N.M., M.M.), Department of Radiation and Medical Sciences, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852– 8523, Japan Sitio web: https://watermark.silverchair.com/jcem1562.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy 7Dm3ZL_9Cf3qfKAc485ysgAAAh4wggIaBgkqhkiG9w0BBwagggILMIICBwIBADCCAgAGCSq GSIb3DQEHATAeBglghkgBZQMEAS4wEQQMxS094zvQrG0MEIV9AgEQgIIB0e2ZtSFod6wf Q_U50AivTvvyd4mX-k7htCEDbUD96xq6fIaNM- xrhPCWzVaXNjlrM17gG9OGEvWLezFaMt_98MIApcHKf8fp8DT5saz-vNGjxiU3Wy- E_aVJCnhamzFpmHXFqHaxZVmQJi9en1h36Y5R20q72vAigAPBBQmq9Ymm8CxTW0OX5A L960iH_SCIuhFPDkh7ehEYHkHS- IuMjNb9sHQ4mLR9XJ1X6os_mDlmsvXQauG1E_jpfqAprVAFdPFfEA7LgxC903jAIOJmshjg3 TVh_91tYHSSammEq3cStoDHN3dkwHkwozL0- N4_dvR0KwFtN8zq6hVQJ3urUZFF9R9gxk7EjC9hYy4ultJMmnh8BsSg_O3LuBtezCNv_x8C3 33UAbsl93r5tR2ce9gOujKZQAA6nfFcSc3DuWEpEXw_ZOsK- x1sRfIJGAugRKHSsZLv_3s86vypZoQgUEX- OEhe89FRnUKVDm5x0QeyPZbpkjDUNS5fKA9uwCLanI- l42NTBXv2H03b4tSkHS3uBbqDG4IsmfFuMMZ5bfRINUvkZPeEcK_kvwkdoRTx_BvN9cczeM 0bpNcOsDaWYELjzrToLYhtUVJY4Tap8hCsKA
X. Marina N. Nikiforova, Abigail I. Wald, Somak Roy, Mary Beth Durso, and Yuri E. Nikiforov. (2013). Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer. Septiembre 2018, de Division of Molecular and Genomic Pathology, Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15261 Sitio web: https://www.ncbi.nlm.nih.gov/pubmed/23979959
XI. YONG WANG1*, QINHAO GUO2*, YAN ZHAO1 , JIEJING CHEN1 , SHUWEI WANG1 , JUN HU1 and YUEMING SUN1. (2014). BRAF activated long non coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Septiembre 2018, de Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000; 2 Department of Obstetrics and Gynecology, Northern Jiangsu Province Hospital, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu 225001, P.R. China Sitio web: https://www.spandidos-publications.com/ol/8/5/1947
XII. Sang Ryung Lee,1 Chan Kwon Jung,corresponding author1 Tae Eun Kim,1 Ja Seong Bae,2 So Lyung Jung,3 Yeong Jin Choi,1 and Chang Suk Kang1. (Junio, 2016). Molecular Genotyping of Follicular Variant of Papillary Thyroid Carcinoma Correlates with Diagnostic Category of Fine-Needle Aspiration Cytology: Values of RAS Mutation Testing. 2018, de Mary Ann Liebest, Inc Publishes Sitio web: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822389/
XIII. Serpil Dizbay Sak . (2015). Variants of Papillary Thyroid Carcinoma: Multiple Faces of a Familiar Tumor. 2018, de Department of Pathology, Ankara University, Faculty of Medicine, Ankara, Turkey Sitio web: http://www.turkjpath.org/pdf/pdf_TPD_1746.pdf
XIV. Noboru Takamura, Makiko Orita, Vladimir Saenko et al.. (Agosto, 2016). Radiation and risk of thyroid cancer: Fukushima and Chernobyl. The Lancet updates, 4, 647. Sitio web: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(16)30112- 7/fulltext#articleInformation
XV. M.R.PelizzoaG.PennellibM.ZaneaF.GaluppinibP.M.CollettidI.Merante BoschinaD.Rubello. (August, 2015). Papillary thyroid carcinoma (PTC) in Lynch syndrome: Report of two cases and discussion on Lynch syndrome behaviour and genetics. 2018, de Department of Oncological Surgery and Gastroenterology (DiSCOG), Clinica Chirurgica II, University of Padova, Padova, Italy Sitio web: https://www.sciencedirect.com/science/article/abs/pii/S0753332215001419 16. Xiaoguang Shi Rengyun Liu Fulvio Basolo Riccardo Giannini Xiaopei Shen Di Teng Haixia Guan Zhongyan Shan Weiping Teng Thomas J. Musholt Khawla Al- Kuraya Laura Fugazzola Carla Colombo Electron Kebebew Barbara Jarzab Agnieszka Czarniecka Bela Bendlova Vlasta Sykorova Manuel Sobrinho-Simões Paula Soares Young Kee Shong Tae Yong Kim Sonia Cheng Sylvia L. Asa David Viola Rossella Elisei Linwah Yip Caterina Mian Federica Vianello Yangang Wang Shihua Zhao Gisele Oler Janete M. Cerutti Efisio Puxeddu Shen Qu Qing Wei Huixiong Xu Christine J. O'Neill Mark S. Sywak Roderick Clifton-Bligh Alfred K Lam Garcilaso Riesco-Eizaguirre Pilar Santisteban Hongyu Yu Giovanni Tallini Elizabeth H. Holt Vasily Vasko Mingzhao Xing. (Junio, 2016). Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants . 2018, de The Journal of Clinical Endocrinology & Metabolism Sitio web: https://academic.oup.com/jcem/article/101/1/264/2806832
XVI. Chunping Liu, Tianwen Chen and Zeming Liu. (06 september 2016). Associations between BRAF V600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World Journal of Surgical Oncology, 12. web:https://wjso.biomedcentral.com/track/pdf/10.1186/s12957-016-0979-1
XVII. http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2014-0612-OA 19. https://academic.oup.com/jcem/article/99/2/E276/2537161 20. https://academic.oup.com/jcem/article/101/11/4413/2765032 21. http://cancerres.aacrjournals.org/content/63/7/1454.full-text.pdf
XVIII. Eun Kyoung Choi Ari Chong Jung Min Ha Chan Kwon Jung Joo Hyun O Sung Hoon Kim. (2017). Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma. 12 de Octubre del 2018, de Korean Society of Nuclear Medicine Sitio web:https://onlinelibrary.wiley.com/doi/full/10.1111/cen.13335
XIX. Robbins y Contran. (2015. 9na edición). Patología estructural y funcional . Madrid: ELSEVIER SAUNDERS. Pag: 1094 - 1097